journal article·2025-08Open access

Advancing cancer immunotherapy: Small-Molecule, biomacromolecular, and nanoscale PROTACs targeting PD-L1 for degradation

Yang Meng, Yujing Zhang, Wanpeng Yu, Dongming Xing, Chao Wang

Abstract

Programmed death-ligand 1 (PD-L1) is a key immune checkpoint protein that enables tumor immune evasion by engaging PD-1 on T cells, thereby inhibiting their cytotoxic function. Although immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have marked a breakthrough in cancer therapy, their effectiveness is often hampered by acquired resistance and immune-related adverse effects. Proteolysis-targeting chimeras (PROTACs) present a transformative approach by catalytically degrading PD-L1 instead of merely blocking its interaction with PD-1, offering a promising strategy to circumvent resistance and amplify therapeutic efficacy. This review systematically examines recent advancements in PD-L1-targeting PROTACs, including small-molecule PROTACs, biomacromolecule PROTACs, and nano-PROTACs, covering molecular design principles, mechanistic underpinnings, and preclinical validation. We also discussed how PD-L1 degradation can improve immunotherapy by regulating the tumor microenvironment (TME) and enhancing T-cell-mediated cytotoxicity. By synthesizing these insights, this review provides a roadmap for developing next-generation precision immunotherapies leveraging targeted protein degradation.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Protein Degradation and Inhibitors · CAR-T cell therapy research · Peptidase Inhibition and Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (84)

Show source-provided references
1. Tumor-infiltrating lymphocyte as a prognostic biomarker in stage IV colorectal cancer should take into account the metastatic status and operation modality10.2147/CMAR.S162147 ↗
2. Overexpression of T lymphoma invasion and metastasis 1 predicts renal cell carcinoma metastasis and overall patient survival10.1007/s00432-010-0895-7 ↗
3. PD-1 and its ligands in tolerance and immunity10.1146/annurev.immunol.26.021607.090331 ↗
4. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection10.1038/ni1443 ↗
5. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial10.1001/jamaoncol.2019.5570 ↗
6. Nivolumab for the treatment of colorectal cancer10.1080/14737140.2018.1480942 ↗
7. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations10.1186/s40425-018-0316-z ↗
8. Recent advances in small molecule based cancer immunotherapy10.1016/j.ejmech.2018.08.028 ↗
9. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies10.1093/annonc/mdv383 ↗
10. Antibody-drug conjugates: current status and future directions10.1016/j.drudis.2013.11.004 ↗
11. Hyperprogression, A challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies10.1016/j.biopha.2022.112949 ↗
12. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade10.1016/j.drup.2022.100907 ↗
13. Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: brightness and challenge10.1007/s11427-019-1622-5 ↗
14. The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling10.1186/s12964-024-01562-5 ↗
15. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions10.1186/s12943-021-01489-2 ↗
16. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours10.1038/s41586-024-08305-z ↗
17. Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer10.3389/fonc.2022.955163 ↗
18. PD-1 blockade induces responses by inhibiting adaptive immune resistance10.1038/nature13954 ↗
19. Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer10.1002/cac2.12244 ↗
20. Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation10.1016/j.molcel.2021.01.010 ↗
21. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers10.3389/fimmu.2022.964442 ↗
22. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges10.1016/j.ejmech.2020.112981 ↗
23. Target and tissue selectivity of PROTAC degraders10.1039/D2CS00200K ↗
24. PROTAC therapy as a new targeted therapy for lung cancer10.1016/j.ymthe.2022.11.011 ↗
25. PROTAC as a novel anti-cancer strategy by targeting aging-related signaling10.1016/j.semcancer.2024.09.004 ↗
26. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation10.1039/D1CS00762A ↗
27. PROTAC 2.0: expanding the frontiers of targeted protein degradation10.1016/j.drudis.2025.104376 ↗
28. PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy10.1186/s12943-022-01707-5 ↗
29. PROTAC unleashed: unveiling the synthetic approaches and potential therapeutic applications10.1016/j.ejmech.2024.116837 ↗
30. PROTAC: Novel degradable approach for different targets to treat breast cancer10.1016/j.ejps.2024.106793 ↗
31. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders10.1039/D2CS00387B ↗
32. PROTAC degraders as chemical probes for studying target biology and target validation10.1039/D2CS00478J ↗
33. Targeted protein degradation: mechanisms, strategies and application10.1038/s41392-022-00966-4 ↗
34. Recent developments in PROTAC-mediated protein degradation: from bench to clinic10.1002/cbic.202100270 ↗
35. Blocking non-enzymatic functions by PROTAC-mediated targeted protein degradation10.1021/acs.jmedchem.2c01159 ↗
36. PROTAC: a novel drug delivery technology for targeting proteins in cancer cells10.2174/1570163820666221031124612 ↗
37. PROTAC-biomacromolecule conjugates for precise protein degradation in cancer therapy: a review10.1016/j.ijbiomac.2024.129864 ↗
38. Recent advances in pro-PROTAC development to address on-target off-tumor toxicity10.1021/acs.jmedchem.3c00302 ↗
39. The state of the art of PROTAC technologies for drug discovery10.1016/j.ejmech.2022.114290 ↗
40. PROTACs: past, present and future10.1039/D2CS00193D ↗
41. Proteolysis-targeting chimeras (PROTACs) in cancer therapy10.1186/s12943-021-01434-3 ↗
42. Proteolysis-targeting chimera (PROTAC): a revolutionary tool for chemical biology research10.1002/smtd.202500402 ↗
43. Methods to accelerate PROTAC drug discovery
44. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy10.1186/s13045-020-00885-3 ↗
45. Small molecule and PROTAC molecule experiments in vitro and in vivo, focusing on mouse PD-L1 and human PD-L1 differences as targets10.1016/j.biopha.2024.116257 ↗
46. Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques10.1016/j.ejmech.2023.115911 ↗
47. PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy10.3389/fimmu.2024.1392546 ↗
48. PROTACs: novel tools for improving immunotherapy in cancer10.1016/j.canlet.2023.216128 ↗
49. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy10.1016/j.ejmech.2021.113967 ↗
50. Recent advances in the design and development of anticancer molecules based on PROTAC technology10.2174/0929867327666200312112412 ↗
51. Targeted protein degrader development for cancer: advances, challenges, and opportunities10.1016/j.tips.2023.03.003 ↗
52. An overview of PROTACs: a promising drug discovery paradigm10.1186/s43556-022-00112-0 ↗
53. Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L110.1016/j.ejmech.2020.112377 ↗
54. In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC)10.1016/j.bioorg.2021.104833 ↗
55. Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1/PD-L1 interaction10.1016/j.bmc.2024.117867 ↗
56. Discovery of novel proteolysis-targeting chimera molecules as degraders of programmed cell death-ligand 1 for breast cancer therapy10.1021/acs.jmedchem.3c02259 ↗
57. Discovery of small molecules for autophagy-lysosome degradation of immune checkpoint proteins10.1016/j.ejmech.2024.116958 ↗
58. PD-L1/SHP2 dual PROTACs inhibit melanoma by enhancing T-cell killing activity
59. Enzyme-activated orthogonal proteolysis chimeras for tumor microenvironment-responsive immunomodulation
60. Tailoring tumor cell golgi apparatus-targeting self-assembled peptide for effective immunotherapy via reshaping MIF-mediated immunosuppressive network
61. Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L110.1021/jacs.0c10008 ↗
62. Roadmap for optimizing and broadening antibody-based PROTACs for degradation of cell surface proteins10.1021/acschembio.2c00185 ↗
63. High-potency PD-1/PD-L1 degradation induced by peptide-PROTAC in human cancer cells10.1038/s41419-022-05375-7 ↗
64. ROTACs leverage signaling-incompetent R-spondin for targeted protein degradation10.1016/j.chembiol.2023.05.010 ↗
65. Stapled peptide PROTAC induced significantly greater anti-PD-L1 effects than inhibitor in human cervical cancer cells10.3389/fimmu.2023.1193222 ↗
66. A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells10.3389/fimmu.2023.1237964 ↗
67. Conditionally activatable chimeras for tumor-specific membrane protein degradation10.1021/jacs.4c06160 ↗
68. Peptide-mediated small molecule lysosome-targeting chimeras for targeted degradation of membrane and intracellular proteins10.1021/acs.jmedchem.4c01449 ↗
69. A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy10.1038/s41467-025-56648-6 ↗
70. Structure-guided development of chemically tailored peptide binders of RNF43/ZNRF3 to enable versatile design of membrane protein-targeting PROTACs10.1002/anie.202501488 ↗
71. Engineering red blood cells for amplified tumor dual-gas transfusion therapy
72. Self-assembled peptide-derived proteolysis-targeting chimera (PROTAC) nanoparticles for tumor-targeted and durable PD-L1 degradation in cancer immunotherapy10.1002/anie.202414146 ↗
73. Programming DNA nanoassemblies into polyvalent lysosomal degraders for potent degradation of pathogenic membrane proteins10.1021/acs.nanolett.4c03102 ↗
74. Targeting intracellular cancer proteins with tumor-microenvironment-responsive bispecific nanobody-PROTACs for enhanced therapeutic efficacy10.1002/mco2.70068 ↗
75. Targeted degradation of PD-L1 and activation of the STING pathway by carbon-dot-based PROTACs for cancer immunotherapy10.1002/anie.202218128 ↗
76. A bifunctional lysosome-targeting chimera nanoplatform for tumor-selective protein degradation and enhanced cancer immunotherapy10.1002/adma.202417942 ↗
77. Frontiers in PROTACs10.1016/j.drudis.2021.04.010 ↗
78. Advancing strategies for proteolysis-targeting chimera design10.1021/acs.jmedchem.2c01555 ↗
79. Small-molecule PROTACs for cancer immunotherapy10.3390/molecules27175439 ↗
80. New-generation advanced PROTACs as potential therapeutic agents in cancer therapy10.1186/s12943-024-02024-9 ↗
81. Targeted protein degradation: from mechanisms to clinic10.1038/s41580-024-00729-9 ↗
82. Targeting the undruggables-the power of protein degraders10.1016/j.scib.2024.03.056 ↗
83. Recent advances in dual PROTACs degrader strategies for disease treatment10.1016/j.ejmech.2024.116901 ↗
84. Proteolysis targeting chimeras (PROTACs) in oncology: a review of patents and regulatory considerations